Literature DB >> 1532417

Brain muscarinic cholinergic receptors in Huntington's disease.

K W Lange1, F Javoy-Agid, Y Agid, P Jenner, C D Marsden.   

Abstract

Muscarinic cholinergic receptors and choline acetyltransferase (ChAT) activity were studied in postmortem brain tissue from patients with Huntington's disease and matched control subjects. In comparison with controls, reductions in ChAT activity were found in the hippocampus, but not in the temporal cortex in Huntington's disease. Patients with Huntington's disease showed reduced densities of the total number of muscarinic receptors and of M-2 receptors in the hippocampus while the density of M-1 receptors was unaltered. Muscarinic receptor binding was unchanged in the temporal cortex. These results indicate a degeneration in Huntington's disease of the septo-hippocampal cholinergic pathway, but no impairment of the innominato-cortical cholinergic system.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1532417     DOI： 10.1007/bf00862983

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  9 in total

1.  Brain muscarinic receptors in Alzheimer's and Parkinson's diseases.

Authors:  K W Lange; F R Wells; M N Rossor; P Jenner; C D Marsden
Journal:  Lancet       Date:  1989-11-25       Impact factor: 79.321

2.  Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia.

Authors:  E D Bird; L L Iversen
Journal:  Brain       Date:  1974-09       Impact factor: 13.501

3.  Subcortical afferent projection systems in Huntington's chorea.

Authors:  D M Mann
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease.

Authors:  T Kuwert; H W Lange; K J Langen; H Herzog; A Aulich; L E Feinendegen
Journal:  Brain       Date:  1990-10       Impact factor: 13.501

5.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia.

Authors:  M Ruberg; A Ploska; F Javoy-Agid; Y Agid
Journal:  Brain Res       Date:  1982-01-28       Impact factor: 3.252

6.  The nucleus basalis in Huntington's disease.

Authors:  A W Clark; I M Parhad; S E Folstein; P J Whitehouse; J C Hedreen; D L Price; G A Chase
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

7.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

Authors:  E K Perry; M Curtis; D J Dick; J M Candy; J R Atack; C A Bloxham; G Blessed; A Fairbairn; B E Tomlinson; R H Perry
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-05       Impact factor: 10.154

8.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

Authors:  E K Perry; B E Tomlinson; G Blessed; K Bergmann; P H Gibson; R H Perry
Journal:  Br Med J       Date:  1978-11-25

9.  Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.

Authors:  E G Spokes
Journal:  Brain       Date:  1980-03       Impact factor: 13.501
  9 in total
  10 in total

1.  M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons.

Authors:  Xiaohui Lv; Jonathan W Dickerson; Jerri M Rook; Craig W Lindsley; P Jeffrey Conn; Zixiu Xiang
Journal:  Neuropharmacology       Date:  2017-03-20       Impact factor: 5.250

2.  Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease.

Authors:  Zhihong Guo; Gay Rudow; Olga Pletnikova; Kari-Elise Codispoti; Brent A Orr; Barbara J Crain; Wenzhen Duan; Russell L Margolis; Adam Rosenblatt; Christopher A Ross; Juan C Troncoso
Journal:  Mov Disord       Date:  2012-09-13       Impact factor: 10.338

3.  Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review.

Authors:  Joe John Vattakatuchery; Renjith Kurien
Journal:  World J Psychiatry       Date:  2013-09-22

4.  RE1-silencing transcription factor controls the acute-to-chronic neuropathic pain transition and Chrm2 receptor gene expression in primary sensory neurons.

Authors:  Jixiang Zhang; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

5.  Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys.

Authors:  Shigeyuki Yamamoto; Shingo Nishiyama; Masahiro Kawamata; Hiroyuki Ohba; Tomoyasu Wakuda; Nori Takei; Hideo Tsukada; Edward F Domino
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

6.  Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties.

Authors:  Esther T Menze; Ahmed Esmat; Mariane G Tadros; Ashraf B Abdel-Naim; Amani E Khalifa
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

Review 7.  Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.

Authors:  Gary X D'Souza; Henry J Waldvogel
Journal:  J Huntingtons Dis       Date:  2016-12-15

8.  Chaperone-Mediated Regulation of Choline Acetyltransferase Protein Stability and Activity by HSC/HSP70, HSP90, and p97/VCP.

Authors:  Trevor M Morey; Warren Winick-Ng; Claudia Seah; R Jane Rylett
Journal:  Front Mol Neurosci       Date:  2017-12-12       Impact factor: 5.639

9.  Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor.

Authors:  Shigeyuki Yamamoto; Yasuomi Ouchi; Daisaku Nakatsuka; Tsuyoshi Tahara; Kei Mizuno; Seiki Tajima; Hirotaka Onoe; Etsuji Yoshikawa; Hideo Tsukada; Masao Iwase; Kouzi Yamaguti; Hirohiko Kuratsune; Yasuyoshi Watanabe
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

10.  Varenicline improves motor and cognitive symptoms in early Huntington's disease.

Authors:  Ailsa L McGregor; Jo Dysart; Malcolm D Tingle; Bruce R Russell; Rob R Kydd; Gregory Finucane
Journal:  Neuropsychiatr Dis Treat       Date:  2016-09-19       Impact factor: 2.570
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.